X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Budesonide
Therapeutic Area: Nephrology Product Name: Nefecon
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $90.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 05, 2020
Details:
Calliditas intends to use the net proceeds for the purposes of funding of its ongoing Phase 3 clinical trial and related trials of Nefecon, pre-commercialization and, if approved, commercialization activities for Nefecon and development of additional product candidates.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Budesonide
Therapeutic Area: Nephrology Product Name: Nefecon
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 14, 2020
Details:
The net proceeds will be used to advance clinical and commercial developments of Calliditas's lead drug, Nefecon, an oral formulation of the corticosteroid budesonide.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
